– UK, Slough – Indivior PLC (LON: INDV) announced the appointment of Dan Ninivaggi to its Board as an Independent Non-Executive Director effective from January 31, 2025.
Mr. Ninivaggi has also joined the Nomination Committee.
About Daniel A. Ninivaggi
Dan Ninivaggi Mr. Ninivaggi has significant public company experience as a director and executive and brings to Indivior a strong background in operations and capital allocation, as well as legal and finance expertise. He is currently Chairman of Garrett Motion Inc. (NASDAQ: GTX), a Switzerland-based supplier of turbochargers and other products designed to improve energy efficiency and reduce emissions in vehicles and industrial equipment. From August 2021 until March 2024, he served as CEO and subsequently the Executive Chairman of Lordstown Motors Corp, an electric vehicle automaker. Before that, Dan Ninivaggi served as the President and CEO of Icahn Enterprises L.P. (IEP) (NASDAQ: IEP), the principal investment vehicle of Carl Icahn, between 2010 and 2014; Co-CEO of Federal-Mogul Holdings Corp. from 2014 until 2017; and CEO of Icahn Automotive Group, LLC and a Managing Director of IEP from 2017 until 2019. Before joining IEP, Daniel Ninivaggi spent six years at Lear Corporation (NYSE: LEA), holding various senior executive positions.
Dan Ninivaggi has served as a director of numerous public and private companies, including Garrett Motion Inc., Lordstown Motors Corp., Hertz Global Holdings Inc., Navistar International Corporation, Icahn Enterprises G.P. Inc., CVR Energy Inc., LLC, XO Holdings, Tropicana Entertainment Inc., Motorola Mobility Holdings Inc., and CIT Group, Inc.
Dan Ninivaggi began his career at Skadden, Arps, Slate, Meagher & Flom LLP before joining Winston & Strawn LLP, where he became a partner specializing in mergers & acquisitions, financing transactions, and corporate governance. He holds a Bachelor of Arts degree from Columbia University, an MBA from the University of Chicago Graduate School of Business, and a law degree (Juris Doctor) (with distinction) from Stanford University School of Law.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide.
For more: https://www.indivior.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.